New Treatment for Advanced Melanoma Shows Promise
The researchers tested pembrolizumab on more than 650 patients in North America, Europe and Australia. They looked at tumor response before and after treatment and found that the lesions were smaller in about one third of patients. In patients who responded to the treatment, seventy-five percent maintained the response at one or two years.
PRESS RELEASE DOWNLOAD
The JAMA Network Media Relations-United Statesmediarelations@jamanetwork.org3124645262